Friday, 16 October 2026European Markets

AVANCE GAS HOLDING Stock Went Up By Over 31% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AVANCE GAS HOLDING (Oslo Børs Benchmark Index_GI: AGAS.OL) jumped by a staggering 31.08% in 21 sessions from kr62.1 to kr81.40 at 10:27 EST on Friday, after five consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.51% to kr1,256.75, after three consecutive sessions in a row of gains.

About AVANCE GAS HOLDING

Avance Gas Holding Ltd, together with its subsidiaries, engages in the transportation of liquefied petroleum gas (LPG). The company transports LPG from the Persian Gulf and the United States Gulf/the United States East Coast to destinations in Europe, South America, India, and Asia. As of December 31, 2021, it owned and operated through a fleet of thirteen very large gas carriers. The company was founded in 2007 and is based in Hamilton, Bermuda. Avance Gas Holding Ltd is a subsidiary of Hemen Holding Ltd.

Earnings Per Share

As for profitability, AVANCE GAS HOLDING has a trailing twelve months EPS of kr9.2.

PE Ratio

AVANCE GAS HOLDING has a trailing twelve months price to earnings ratio of 8.85. Meaning, the purchaser of the share is investing kr8.85 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for AVANCE GAS HOLDING is 62907 which is 0.69% above its average volume of 126538.

More news about AVANCE GAS HOLDING (AGAS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com